{"entity":{"id":"azd3470","kind":"drug","name":"AZD3470","aka":[],"tldr":"AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).","summary":"AZD3470 is a small-molecule drug developed by AstraZeneca. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency. ClinicalTrials.gov describes the intervention as: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hodgkin lymphoma and peripheral T-cell lymphomas. The largest, NCT06130553, plans to enrol 334 participants with primary completion expected 2028-12-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD3470","url":"https://clinicaltrials.gov/search?intr=AZD3470"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":["prmt5-mtap"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06137144","nct06130553"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd3470/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"target":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/"},{"id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/"}]}}